Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.2 USD | -0.28% | -0.11% | -0.44% |
Apr. 15 | Truist Securities Adjusts Zimmer Biomet Price Target to $137 From $135, Hold Rating Kept | MT |
Apr. 04 | Zimmer Biomet Partners with Three Pickleball Organizations in US | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
Weaknesses
- With a 2024 P/E ratio at 23.16 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.72 times its current sales, is high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.44% | 24.9B | B | ||
-2.89% | 185B | C+ | ||
-2.43% | 107B | C | ||
-4.10% | 67.55B | A | ||
+11.10% | 54.6B | B- | ||
+15.86% | 47.42B | B- | ||
+3.86% | 42.24B | B+ | ||
+9.55% | 28.24B | A- | ||
+1.85% | 26.42B | B | ||
+12.40% | 25.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZBH Stock
- Ratings Zimmer Biomet Holdings, Inc.